RxDoctor Payments Data

Edward Stoner, MD

Internal Medicine · East Windsor, NJNPI 1467427450

Payments from drug & device makers

$695in general payments, 2019–2025

Across 33 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$236
  • Avanir Pharmaceuticals, Inc.$199
  • AstraZeneca$55
  • Merck$44
  • Amarin Pharma, Inc.$43
  • Exact Sciences$32
  • plus $86 from 5 others

What the payments were for

  • Food & beverage$695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$48,677
Medicare patients
198
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AtivanLorazepam12$76,318
OzempicSemaglutide22$29,524
JardianceEmpagliflozin17$13,581
JanuviaSitagliptin Phosphate14$12,176
Janumet XrSitagliptin Phos/Metformin Hcl11$6,063
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,149
Rosuvastatin Calcium48$715
Losartan Potassium85$700
Atorvastatin Calcium80$655
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic11$634
Escitalopram Oxalate34$540
Amlodipine Besylate80$524
Metoprolol Succinate37$392
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12$351
Allopurinol29$341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$236$29,52422 claims
MerckJanuvia, Janumet Xr$44$18,23925 claims
Boehringer IngelheimJardiance$17$13,58117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in East Windsor

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →